Clinical phase 1/2 trials: Inhibition of Tim-3/galectin-9 interaction prevents T cell inhibition and enhances anti-tumor immunity in combination with anti-PD1 and -PDL1 therapy. The gene discussed is HAVCR2; the disease is neoplasm.